kras mutant inhibitor qtx3034
Generic: KRAS Mutant Inhibitor QTX3034
kras mutant inhibitor qtx3034: 1 clinical trial tracked.
kras mutant inhibitor qtx3034 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kras mutant inhibitor qtx3034, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Interventionalopen250 targetStarted 2024-02Completion 2027-0414 sites · United StatesQuanta Therapeutics